tbuckley/cabot-search huggingface dataset:
Identification of Mammaglobin as a Novel Serum Marker for Breast Cancer
Authors: Jonine L. Bernstein, James H. Godbold, George Raptis, Mark A. Watson, Brooke Levinson, Stuart A. Aaronson, Timothy P. Fleming
Journal: Clinical Cancer Research (2005)

Abstract Purpose: Early detection of breast cancer has implications for the management and treatment of patients with this disease. Currently, there exist no highly sensitive and specific serologic biomarkers for detection of breast cancer. Mammaglobin is predicted to be a secreted protein, and expression of this gene seems to be highly specific in breast cancer. The present studies were undertaken to develop the mammaglobin protein as a serum biomarker for detection of breast cancer. Experimental Design: We characterized the mammaglobin protein as a secreted, 14- to 21-kDa species, which is likely post-translationally processed based on its predicted 7-kDa size. Immunostaining for mammaglobin was conducted. An ELISA was developed for the detection of the mammaglobin protein in serum, and levels were compared between women with and without breast cancer. A receiver operating characteristic curve was used to show sensitivity and specificity for cut points on the continuous mammaglobin scale. Results: The protein was detectable by immunostaining in 72% of breast tumors and not in other tumor types. The ELISA was highly sensitive and specific for detection of mammaglobin protein in tissue culture fluids of breast cancer cells and sera of breast cancer patients. The ELISA differentiated healthy women from those with breast cancer with accurate, repeatable results across time and under varying storage conditions. Conclusion: Our results indicate that mammaglobin, as measured by the ELISA, holds significant promise for breast cancer screening with the realistic potential to impact management of this disease.
PERMANENT ENLARGEMENT OF THE LIPS AND FACE
Authors: Gordon B. New
Journal: JAMA (1933)

<h3>To the Editor:</h3> —Referring to the communication by Dr. Pusey (The Journal, May 20, p. 1626), I feel that I should reply, for it is apparent that Dr. Pusey failed to recognize the entity that Dr. Kirch and I described (The Journal, April 22, p. 1230). The condition to which Dr. Pusey referred, and which is secondary to erysipelas and lymphangitis, is indeed well known to the medical profession in general, and to Dr. Kirch and me, for we have seen many such cases at the Mayo Clinic. We have given surgical treatment for the condition which we described, and the fact that the responsibility for the results of such treatment would rest directly on us has made us particularly careful to exclude cases in which the condition had originated with erysipelas or lymphangitis. Nevertheless, we have not been so self confident as to proceed to surgical treatment without having
Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients.
Authors: Clifford D. Jones, Kevin Blades, Kevin M. Foote, Sylvie M. Guichard, Philip J. Jewsbury, Thomas McGuire, Johannes W. Nissink, Rajesh Odedra, Kin Tam, Pia Thommes, Paul Turner, Gary Wilkinson, Christine Wood, James W. Yates
Journal: Cancer Research (2013)

Abstract AZD6738 is a potent and selective inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase with the potential to be used in the clinic. We report the discovery of a morpholino-pyrimidine series and its subsequent optimisation to the pre-clinical candidate AZD6738 which has a good overall balance of potency, selectivity, pharmacokinetic and biopharmaceutical properties suitable for oral dosing. ATR is a serine/threonine protein kinase involved in DNA damage response signalling caused by DNA replication associated stress. Activation of ATR at stalled replication forks leads to suppression of replication fork origin firing, promotes repair and S/G2-cell cycle checkpoints to prevent premature mitosis and maintain genomic integrity. Failure to resolve damage leads to genomic instability and if sufficiently high, cell death. Stalled replication forks may collapse leading to formation of DNA double stranded breaks and activation of the ataxia telangiectasia mutated (ATM) kinase. ATM works in conjunction with ATR to efficiently resolve replication associated DNA damage creating a co-dependency with loss of one leading to a greater reliance on the other to maintain genomic stability. ATM is frequently inactivated across B-cell malignancies, head and neck, breast and lung cancers through chromosomal deletion, promoter hypermethylation or mutation. ATM-deficient tumours are hypothesised to be more reliant on ATR for survival and specific inhibition of ATR may lead enhanced anti-tumour activity while minimizing normal tissue toxicity. AZD6378 has the potential to test the clinical efficacy of ATR inhibition in cancer patients as monotherapy against ATM-deficient tumours or in combination with chemo or radiotherapy. Citation Format: Clifford D. Jones, Kevin Blades, Kevin M. Foote, Sylvie M. Guichard, Philip J. Jewsbury, Thomas McGuire, Johannes W. Nissink, Rajesh Odedra, Kin Tam, Pia Thommes, Paul Turner, Gary Wilkinson, Christine Wood, James W. Yates. Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2348. doi:10.1158/1538-7445.AM2013-2348
Adjuvant Chemotherapy for Stage II and III Breast Carcinoma
Authors: Joseph A. Caprini
Journal: JAMA (1980)

Stage II or III breast carcinoma patients were assigned to one of three adjuvant chemotherapy groups after mastectomy. The efficacy of melphalan, vs cyclophosphamide, fluorouracil, and prednisone (CFP), vs CFP plus BCG vaccine was compared in 173 patients treated for five days every six weeks for the first postoperative year. Tumor size, unfavorable local signs, extent of axillary nodal involvement, menopausal status, and participating hospital were considered in assigning patients to treatment groups. The median follow-up time was 26 months; 24.2% of the patients were studied for more than three years. Recurrent disease occurred in 31.6% of the patients in the melphalan group and in 13.4% and 13.2% in the other two groups. Six patients died of metastatic tumor; three others died of other causes. A favorable significant difference exists for polychemotherapy in prolonging disease-free interval in our series.
MYCETOMA (MADURA FOOT) IN THE YEMEN
Authors: F. G. Clemow
Journal: BMJ (1906)

In case of haemoptysis with a high-tension pulse, could we rationally, and with a due sense of our responsibilities, give so powerful a pressure-raiser as the suprarenal?And in lung bleeding with low pressure-probably the more usual case-should we not rather assist Nature by lowering circulatory tension by any means in our power than empirically use a drug which, though powerful for much good, when rightly and rationally used, is also capable of much harm.
Treatment Strategy for “Non-Responders” to Tadalafil and Vardenafil: A Real-Life Study
Authors: Konstantinos Hatzimouratidis, Kyriakos Moysidis, Athanasios Bekos, Zoi Tsimtsiou, Evangelos Ioannidis, Dimitrios Hatzichristou
Journal: European Urology (2006)
Abstract 1957: Slug regulates SOX9 stability in lung carcinoma and its involvement in the regulation of cancer stem cells and lung metastasis
Authors: Sudjit Luanpitpong, Liying Wang, Yon Rojanasakul
Journal: Cancer Research (2014)

Abstract Most solid tumors including lung carcinoma are believed to contain cancer stem cells (CSCs) that are responsible for tumor initiation, progression, and metastasis. Understanding how CSCs are regulated at the molecular level may lead to novel strategies for cancer therapy. We have identified two proteins, Slug and SOX9, which determine the CSC state of human lung cancer epithelial cells. Inhibition of either Slug or SOX9 sufficiently blocks CSCs in human lung carcinoma cell lines, as determined by side population and tumor sphere assays, and attenuates lung metastasis in vivo in a xenograft mouse model. Coexpression of Slug and SOX9 is detected in the majority of lung tissues with advanced stage carcinoma. Here we found for the first time that Slug regulates SOX9 stability. Loss of Slug results in SOX9 degradation through ubiquitin-proteasomal pathway, and overexpression of Slug conversely prevents SOX9 degradation. Together, our results provide a direct evidence for the control of CSCs and tumor progression by Slug and SOX9, and unveil a novel role of Slug in SOX9 stabilization. These findings provide a mechanistic insight to the pathogenesis of metastasis in advanced lung carcinoma. Citation Format: Sudjit Luanpitpong, Liying Wang, Yon Rojanasakul. Slug regulates SOX9 stability in lung carcinoma and its involvement in the regulation of cancer stem cells and lung metastasis. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1957. doi:10.1158/1538-7445.AM2014-1957
Responsibility of Lawyers in Malpractice Suits
Authors: E. S. Gurdjian
Journal: JAMA (1964)

To the Editor:—  I recently read a newspaper account of a paper given at the AMA meeting in San Francisco concerning malpractice suits against physicians. According to the authors, part of the hostility of lawyers toward the medical profession may be due to the fact that law does not rank as high in the community as medicine and that therefore attorneys are envious and glad to make trouble for physicians. Such pronouncements by physicians do nothing to clear the air, but tend instead to cause more difficulties between lawyers and physicians.  The statements about reluctance of doctors to treat attorneys who specialize in malpractice suits, and about judges favoring lawyers since they themselves are lawyers, are not true. Judges are fair and work in the best interest of all concerned.  I agree with the authors that something should be done to lower the incidence of malpractice suits. Possibly some courses
Idiopathic prolapsed mitral leaflet syndrome. Angiographic-clinical correlations.
Authors: N Ranganathan, M D Silver, T I Robinson, J K Wilson
Journal: Circulation (1976)

Angiographic clinical correlations were made in 59 patients with prolapsed mitral leaflet syndrome. Eight had nonejection systolic clicks (group I), 20 had early, mid or late systolic murmurs with or without a systolic click (group II), and 31 had pansystolic murmurs (group III). Isolated prolapse of posterior leaflet (PL) scallops occurred in 42 and 17 had combined leaflet prolapse. The study demonstrated the following: (I) Group II patients usually had isolated PL prolapse with a predominant biscallop involvement while a high incidence of triple scallop prolapse and combined mitral leaflet prolapse occurred in group III. (II) Severe mitral regurgitation and a greater incidence of atrial fibrillation were seen in patients with triscallop prolapse and combined mitral leaflet prolapse. Mitral regurgitation was milder in patients with single and biscallop prolapse and, when severe, was associated with ruptured chordae. (III) ST-T wave abnormalities in the inferior leads were most frequent in patients with isolated PL prolapse. (IV) Systolic and diastolic asynergy occurred in 41 patients, most frequently in group II but also relatively frequently in group III (19 of 31). Segmental anterior dysfunction with normal ejection fraction was found in 18 patients, of whom 13 had early anterior wall relaxation. (V) Patients without asynergy were slightly older than those with it. More in the former group had severe mitral regurgitation and were clinically disabled from it.
Inhalative Exposure to Vanadium Pentoxide Causes DNA Damage in Workers: Results of a Multiple End Point Study
Authors: Veronika A. Ehrlich, Armen K. Nersesyan, Christine Hoelzl, Franziska Ferk, Julia Bichler, Eva Valic, Andreas Schaffer, Rolf Schulte-Hermann, Michael Fenech, Karl-Heinz Wagner, Siegfried Knasmüller
Journal: Environmental Health Perspectives (2008)

Inhalative exposure to vanadium pentoxide (V(2)O(5)) causes lung cancer in rodents.The aim of the study was to investigate the impact of V(2)O(5) on DNA stability in workers from a V(2)O(5) factory.We determined DNA strand breaks in leukocytes of 52 workers and controls using the alkaline comet assay. We also investigated different parameters of chromosomal instability in lymphocytes of 23 workers and 24 controls using the cytokinesis-block micronucleus (MN) cytome method.Seven of eight biomarkers were increased in blood cells of the workers, and vanadium plasma concentrations in plasma were 7-fold higher than in the controls (0.31 microg/L). We observed no difference in DNA migration under standard conditions, but we found increased tail lengths due to formation of oxidized purines (7%) and pyrimidines (30%) with lesion-specific enzymes (formamidopyrimidine glycosylase and endonuclease III) in the workers. Bleomycin-induced DNA migration was higher in the exposed group (25%), whereas the repair of bleomycin-induced lesions was reduced. Workers had a 2.5-fold higher MN frequency, and nucleoplasmic bridges (NPBs) and nuclear buds (Nbuds) were increased 7-fold and 3-fold, respectively. Also, apoptosis and necrosis rates were higher, but only the latter parameter reached statistical significance.V(2)O(5) causes oxidation of DNA bases, affects DNA repair, and induces formation of MNs, NPBs, and Nbuds in blood cells, suggesting that the workers are at increased risk for cancer and other diseases that are related to DNA instability.
Twenty steps towards a "closed society" on health.
Authors: R Smith
Journal: BMJ (1987)

engenders in those men and women who were sustained through the last war by the ideal of a future society free of want, disease, ignorance, squalor, and idleness.How do they respond when their first sight of a hospital is of two student nurses and a patient's relative struggling with two trolleys, a closed children's ward on one side, a condemned lift on the other, and between them and the x ray department an obstacle course of buckets and basins carefully positioned under a leaking roof?I cannot tell you that, and I cannot tell you from where the people who work there get their resources ofpoliteness and humanity.And from what I saw I cannot tell you how long everyone is prepared to stick it.
Reiter's syndrome: long-term follow-up data.
Authors: B Amor
Journal: Annals of the Rheumatic Diseases (1979)

There is no big difference between our data in a long-term follow-up of 155 patients with Reiter's syndrome (RS) seen at the rheumatic disease unit of the Hopital Cochin in Paris and those of Dr Csonka.For each patient articular and extra- articular manifestations of RS are entered on a synoptic view as they appear throughout the years (Fig. 1).In the next set of figures each curve repre- sents the fluctuations in incidence of a single sign or symptom in terms of per cent positives throughout the years.As was to be expected, the incidence of urethritis (Fig. 2) is high at the onset of the disease.Uveitis is not a common feature in the first years of RS.It occurs, in our experience, after five to ten years, while urethritis can be part of very late relapses also.Concerning mucocutaneous symptoms (Fig. 3), skin manifestations become more frequent later in the disease, and some patients will develop real psoriasis after 10 years.Fig. 4 depicts the joint manifestations throughout the years.There is a 0 1 2 3 4 5 6 7 8 9 10 1 1 12 13 14 15 16 Duration (years) 0 -Lymphocyte blast transformation to Chlamydia antigen "test de transformation lymphoblastique"02 Gonococcal urethritis 0 E13 E3 copyright.
Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity
Authors: D Cilloni, S Carturan, C Maffè, F Messa, F Arruga, E Messa, M Pradotto, M Pautasso, C Zanone, P Fornaciari, I Defilippi, A Rotolo, E Greco, I Iacobucci, G Martinelli, F Lo-Coco, E Bracco, G Saglio
Journal: Leukemia (2010)
Hepatic Hepatitis C Virus RNA in Chronic Hepatitis C
Authors: Michiko Shindo
Journal: Annals of Internal Medicine (1996)

Letters1 January 1996Hepatic Hepatitis C Virus RNA in Chronic Hepatitis CMichiko Shindo, MD, PhD and Tadao Okuno, MD, PhDMichiko Shindo, MD, PhDAkashi Municipal Hospital; Akashi, Hyogo 673, JapanSearch for more papers by this author and Tadao Okuno, MD, PhDAkashi Municipal Hospital; Akashi, Hyogo 673, JapanSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We thank Craxi and colleagues for providing interesting information. We have been following 10 patients with chronic hepatitis C who received interferon-α and became long-term responders with detectable HCV RNA for 1.5 to 3 years. No patient had subsequent relapse, even with their detectable HCV RNA. We therefore agree with Craxi and colleagues that late alanine aminotransferase relapse is uncommon.As we described in our article, liver histologic findings significantly improved in all long-term responders at the end of therapy, regardless of the presence of HCV RNA. However, we saw further improvement only in the long-term responders who ... Author, Article, and Disclosure InformationAffiliations: Akashi Municipal Hospital; Akashi, Hyogo 673, Japan PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMedical Heuristics: The Silent Adjudicators of Clinical Practice Clement J. McDonald Metrics Cited ByClinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy 1 January 1996Volume 124, Issue 1_Part_1Page: 72KeywordsChronic hepatitisChronic hepatitis CDrugsHepatitis C virusHepatocellular carcinomaInterferonsLesionsLiverRNAUltrasound imaging Issue Published: 1 January 1996 CopyrightCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
The importance of prompt CPR in cardiac arrest
Authors: D. M. Sado, J. Moon, S. Woldman
Journal: BMJ (2012)

European public interest has recently focused on cardiac arrest in the overtly healthy, after a succession of events in high profile sporting arenas.

Currently in Europe, around 10% of people survive an out of hospital cardiac arrest, with the most important determinant of success being the presence of a trained lay rescuer who is “ready, willing, and able to act.”1

Herein lies a problem; …
Valvular Aortic Stenosis as a Major Sequelae in Patients With Pre-Existing Subaortic Stenosis
Authors: Zachary W.M. Laksman, Candice K. Silversides, Tara Sedlak, Ahmed M. Samman, William G. Williams, Gary D. Webb, Peter P. Liu
Journal: Journal of the American College of Cardiology (2011)
'Lanolin' and 'Parabens' in pharmaceutical and cosmetic products
Authors: Susan Evans
Journal: British Journal of Dermatology (1987)

Journal Article ‘Lanolin’ and ‘Parabens’ in pharmaceutical and cosmetic products Get access Susan Evans Susan Evans The Skin Department, Newsham General Hospital, Belmont Road, Liverpool L6 4AF, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 116, Issue 2, 1 February 1987, Pages 278–279, https://doi.org/10.1111/j.1365-2133.1987.tb05832.x Published: 01 February 1987
Effect of Transient Resistance Changes on Atrial Septal Defects and Other Intracardiac Shunts
Authors: R. M. McCredie
Journal: Cardiovascular Research (1967)

Journal Article Effect of Transient Resistance Changes on Atrial Septal Defects and Other Intracardiac Shunts Get access R. M. McCredie R. M. McCredie † From the Hallstrom Institute of Cardiology, Royal Prince Alfred Hospital, Camperdown, N.S.W., Australia † Present address for reprints: The Prince Henry Hospital, Little Bay, N.S.W., Australia. Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 1, Issue 4, October 1967, Pages 335–340, https://doi.org/10.1093/cvr/1.4.335 Published: 01 October 1967 Article history Received: 02 January 1967 Published: 01 October 1967
5. Clinical performance of fluticasone propionate nasal drops
Authors: M. Holmström
Journal: Allergy (1999)

The efficacy and safety of fluticasone propionate (FP) nasal drops were investigated in two multicentre, randomized, placebo‐controlled trials. Patients received FP 400 μg once or twice daily for 12 weeks and then FP 400 μg once daily for a further 12 weeks. FP 400 μg significantly reduced polyp size and improved peak nasal inspiratory flow, rhinitis symptoms and sense of smell when administered twice daily. Significant reductions in polyp size were not achieved with once daily administration, but clinical benefits were observed for peak nasal inspiratory flow. Both dosing regimens were well tolerated, with an overall incidence of adverse events which was similar to placebo.
Oral Absorption of Commercial Buffered Aspirin Tablets
Authors: Win L. Chiou
Journal: JAMA (1973)

<h3>To the Editor.—</h3> Several buffered aspirin products are available on the market. Among them "Alka-Seltzer" and "Bufferin" are the most advertised and expensive. Since aspirin in Alka-Seltzer is administered in solution form, its rapid and complete absorption has been well established. So far as we know, the superiority of Bufferin over other generic buffered aspirins, in terms of absorption and clinical efficacy, has not been confirmed. In fact, the validity of television advertisement claims of Bufferin and some other aspirin products have been recently challenged by the Federal Trade Commission. We have recently performed an oral absorption study of Bufferin and four generic buffered aspirin products purchased from department stores, supermarkets, and a retail pharmacy in the Chicago area on seven healthy adult subjects (aged 23 to 34 years) in a crossover manner separated by one week between each trial. Two 5-grain tablets containing approximately 650 mg of aspirin were